Clinical studyShort-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses☆
Introduction
Pathologic and imaging studies suggest that development of permanent neurologic impairment or disease progression in multiple sclerosis (MS) is associated with progressive brain and spinal cord atrophy. Tissue atrophy has been identified in the early stages of the disease process.1 Atrophy is thought to reflect irreversible axonal loss2 and has been shown to correlate better with clinical disability, as measured by the Expanded Disability Status Score (EDSS),3 than lesion load measurements. As a result, cerebral volume measurement is increasingly being used as a surrogate marker of tissue destruction and disease progression in MS treatment trials. While most treatment trials permit intravenous methylprednisolone (IVMP) administration for the treatment of clinical relapses, the effect on measured cerebral volumes of such treatment has only recently been reported in three retrospective studies.[4], [5], [6] We report the first prospective study addressing this issue.
Section snippets
Methods
We prospectively recruited patients with clinically definite MS, according to the Poser criteria, who were suffering an acute relapse. A relapse was defined as worsening of neurological function for more than 48 h prior to recruitment that, in the opinion of the treating neurologist, required treatment with IVMP. The patients were given IVMP (1 g daily for 3 days). All underwent serial, non-enhanced, MRI brain studies performed within 24 h pre- and post-IVMP, and 4 and 8 weeks later. Clinical
Results
Ten patients were recruited and a total of 40 cerebral MRI studies were evaluated. There were two men and eight women (mean age, 39.4 years; range, 23–59). Mean duration of disease was 6.3 years (range, 1.5–10 years). Eight of the 10 patients were taking a disease-modifying agent (interferon or glatiramer acetate). Four patients had entered the secondary progressive phase of the disease but continued to have relapses. As expected, the EDSS scores improved after treatment in the majority of
Discussion
This prospective pilot study demonstrated that IVMP administration in MS patients experiencing a clinical relapse was associated with a statistically significant reduction in measured cerebral volume over the 8-week study period. The greatest change in cerebral volume occurred during the 3-day period of steroid administration. These findings are consistent with those of Rao et al.5 who retrospectively examined the brain fraction volume (BFV) before and after IVMP in patients with relapsing
Acknowledgement
Caron Chapman is funded by the Schering Multiple Sclerosis Research Fellowship provided by the Melbourne Neuroscience Research Centre, Melbourne University.
References (10)
- et al.
Brain atrophy in clinically early relapsing-remitting multiple sclerosis
Brain
(2002) - et al.
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
Brain
(2002) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)
Neurology
(1983)- et al.
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
Neurology
(2001) - et al.
Effect of intravenous methylprednisolone on MRI measures of disease activity in RRMS patients before and after interferon beta-1b
Neurology
(2002)
Cited by (12)
The Cognitive, Psychological, and Emotional Presentation of Cushing's Disease
2017, Cushing's Disease: An Often Misdiagnosed and Not So Rare DisorderMultiple Sclerosis
2008, Essentials of Physical Medicine and RehabilitationMultiple Sclerosis
2008, Essentials of Physical Medicine and Rehabilitation: Musculoskeletal Disorders, Pain, and Rehabilitation, Second EditionGlucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations
2023, Journal of Endocrinological InvestigationAssessment of brain and hippocampal volume in patients with Cushing's disease
2022, Endokrynologia Polska
- ☆
Schering Multiple Sclerosis Research Fellowship provided by the Melbourne Neuroscience Research Centre, Melbourne University. Support from the Neuroscience Foundation, The Royal Melbourne Hospital.